Placental Growth Factor (PlGF) and Its Receptor Flt‐1 (VEGFR‐1)

@article{Luttun2002PlacentalGF,
  title={Placental Growth Factor (PlGF) and Its Receptor Flt‐1 (VEGFR‐1)},
  author={Aernout Luttun and Marc Tjwa and Peter Carmeliet},
  journal={Annals of the New York Academy of Sciences},
  year={2002},
  volume={979}
}
Abstract: Efforts to therapeutically stimulate or inhibit vessel growth have been primarily focused on vascular endothelial growth factor (VEGF) and its receptor VEGFR‐2 (Flk‐1), while little attention has been devoted to the therapeutic potential for angiogenic disorders of placental growth factor (PlGF), a VEGF family member, and its receptor VEGFR‐1 (Flt‐1). However, recent developments and insights could shift that focus to P1GF and Flt‐1. Indeed, PlGF stimulated angiogenesis and collateral… 
View on Wiley
181 Citations
Highly Influential Citations
4
Background Citations
22
Results Citations
1

181 Citations

Placental growth factor and its receptor, vascular endothelial growth factor receptor‐1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders
TLDR
Preclinical studies show proof‐of‐principle that PlGF and VEGFR‐1 are promising therapeutic targets to treat angiogenesis and inflammation related disorders and whether this is also true for patients.
Modulation of Angiogenesis by a Tetrameric Tripeptide That Antagonizes Vascular Endothelial Growth Factor Receptor 1*
TLDR
A tetrameric tripeptide from a combinatorial peptide library built using non-natural amino acids, which binds Flt-1 and inhibits in vitro its interaction with placental growth factor and vascular endothelial growth factor A and B, and is able to stimulate corneal mouse neovascularization in physiological condition.
Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: a link between angiogenesis and inflammation.
TLDR
Enhanced expression of PlGF and flt-1 may contribute to rheumatoid inflammation by triggering production of proinflammatory cytokines, and the use of the novel anti-flt-1 peptide, GNQWFI, may be an effective strategy for the treatment of RA.
Clinical Efficacy and Safety of Angiogenesis Inhibitors: Sex Differences and Current Challenges.
TLDR
Current challenges clinicians are facing with regard to angiogenesis inhibitor treatments, including the need to consider sex differences affecting clinical efficacy and safety are discussed, and areas for future research taking into account the role of sex hormone receptors and sex chromosomes are proposed.
VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition
TLDR
This chapter will review the biological role of VEGFR and PDGFR signal transduction and the interplay between the different receptors as it relates to kidney cancer.
Identification of Placenta Growth Factor Determinants for Binding and Activation of Flt-1 Receptor*
TLDR
The first detailed mutagenesis studies that provide a basis for understanding molecular recognition between PlGF-1 and Flt-1 are reported, highlighting some of the residues that are critical for receptor recognition.
Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation.
TLDR
It is suggested that ANG II stimulates angiogenesis via transactivation of the EGF receptor, which promotes the phosphorylation of Flt-1 and activation of Syk independent of VEGF expression.
The Anti–Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo
TLDR
D16F7 was able to inhibit receptor activation and migration and extracellular matrix invasion of C6 cells overexpressing the receptor in response to PlGF and VEGF-A and was associated with glioma cell apoptosis and decreased tumor-associated vessel formation.
Anti-Flt1 Peptide, a Vascular Endothelial Growth Factor Receptor 1–Specific Hexapeptide, Inhibits Tumor Growth and Metastasis
TLDR
The effects on endothelial cell functions, in vitro, indicate that the anticancer activity of anti-Flt1 peptide with reduced blood vessel density could also be due to the blocking of VEGFR1-mediated endothelium cell migration and tube formation.
Vascular Endothelial Growth Factors and the Bmx Tyrosine Kinase in the Regulation of Angiogenesis and Lymphangiogenesis
TLDR
The results suggest that Bmx expression, that has been detected in prostate carcinomas, could be associated with important aspects of tumor progression and that VEGF-C is induced by various proinflammatory cytokines and growth factors and that it and its receptor VEGFR-3 could be involved in the pathogenesis of inflammatory processes.
...
...

References

SHOWING 1-10 OF 42 REFERENCES
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
TLDR
It is reported that embryonic angiogenesis in mice was not affected by deficiency of PlGF, andTransplantation of wild-type bone marrow rescued the impairedAngiogenesis and collateral growth in Pgf−/− mice, indicating that PlGF might have contributed to vessel growth in the adult by mobilizing bone-marrow–derived cells.
Functions of the VEGF receptor-1 (FLT-1) in the vasculature.
  • M. Clauss
  • Biology
    Trends in cardiovascular medicine
  • 1998
Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis.
TLDR
Flt-1 has a dual function in angiogenesis, acting in a positive or negative manner in different biological conditions, as well as a positive regulator using its tyrosine kinase under pathological conditions when the Flt-1-specific ligand is abnormally highly expressed.
Expression of vascular endothelial growth factor receptors in smooth muscle cells
TLDR
The studies demonstrate the presence of VEGF receptors on VSMCs that are functional and indicate that in vivo, V EGF may play a role in modulating the response of VSMC's.
Role of vascular endothelial growth factor in regulation of physiological angiogenesis.
  • N. Ferrara
  • Biology
    American journal of physiology. Cell physiology
  • 2001
TLDR
Evidence accumulating over the last decade has established the fundamental role of vascular endothelial growth factor (VEGF) as a key regulator of normal and abnormal angiogenesis, and numerous clinical trials are presently testing the hypothesis that inhibition of VEGF may have therapeutic value.
Structure and function of VEGF/VEGF-receptor system involved in angiogenesis.
  • M. Shibuya
  • Biology, Medicine
    Cell structure and function
  • 2001
TLDR
Further studies on VEGF-VEGF receptor system may significantly facilitate the understanding on the physiological as well as pathological vascular systems in the body and the development of new strategies to control and suppress the major diseases in humans.
Angiozyme: A Novel angiogenesis inhibitor
TLDR
In animal tumor models, antitumor effects are most pronounced with the anti-Flt-1 ribozyme known as Angiozyme, which is currently in progress for patients with advanced malignancy.
Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury.
TLDR
Although VEGF did not increase collateral development as administered in this study, it significantly exacerbated neointimal accumulation, which provides support for the clinical investigation of bFGF in selected patients with ischemic heart disease.
Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy.
TLDR
KDR/Flk-1 was only weakly associated with normal developing primary retinal vessels but was strongly expressed by proliferating endothelial cells in reformingretinal vessels and intravitreal neovascularization after hyperoxic insult, suggesting that blocking KDR may be beneficial for treating pathologic angiogenesis in adult tissue.
Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice.
TLDR
Results indicate that Flt-1 without tyrosine kinase domain is sufficient to allow embryonic development with normal angiogenesis, and that a receptor tyrosin kinase plays a main biological role as a ligand-binding molecule.
...
...